NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its Phase IIA clinical trial of NV-387 Oral Gummies for Ebola Bundibugyo virus disease in the Democratic Republic of Congo (DRC) is progressing, with advancement to Phase IIB anticipated after the initial phase concludes. Enrollment began on Sept. 23, 2026, and approximately 20 patients are expected to participate in Phase IIA, which is designed to evaluate dosing regimens based on disease severity. The primary endpoint is 28-day survival, and the initial phase will end once the final enrolled patient completes the observation period.
The company emphasized the potential significance of an oral antiviral amid the ongoing Ebola Bundibugyo outbreak, which has resulted in more than 10,000 confirmed cases and approximately 4,900 deaths in the DRC. NanoViricides stated that no treatments or vaccines are currently approved specifically for Ebola Bundibugyo and that NV-387 Oral Gummies is, to its knowledge, the only oral drug candidate undergoing clinical evaluation for the disease. The company is also evaluating NV-387 Oral Gummies in a separate Phase II trial for mpox in the DRC.
For investors and industry observers, the update offers a window into the challenges and potential of developing therapies for neglected infectious diseases. The lack of approved options for Ebola Bundibugyo underscores the unmet medical need, and a successful oral treatment could simplify administration in outbreak settings where healthcare infrastructure is strained. However, the company notes that drug development is lengthy and capital-intensive, and there can be no assurance that any candidate will demonstrate sufficient safety and efficacy for human clinical development.
NanoViricides is developing its nanoviricide class of drug candidates based on technology licensed from TheraCour Pharma, Inc. Its lead candidate, NV-387, is a broad-spectrum antiviral being developed for respiratory viral infections, mpox/smallpox, and other diseases. The company’s pipeline also includes NV-HHV-1 for shingles. The Phase IIA Ebola trial represents a critical step in testing the oral gummy formulation in a real-world outbreak context.
The announcement comes as BioMedWire, a specialized communications platform focused on biotechnology and life sciences, highlighted the development. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. The platform aims to connect private and public companies with investors, influencers, and the public.
For those following NanoViricides, the latest news and updates are available in the company’s newsroom. The full press release can be viewed at https://ibn.fm/JJ69W. As with any drug development effort, there can be no assurance that the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development.
